Granules Life Sciences facility receives EIR from USFDA

This approval confirms the facility's compliance with FDA quality standards and regulatory requirements

Granules Life Sciences Private Limited (GLS), a wholly owned subsidiary of Granules India Limited situated in Hyderabad, has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the first inspection conducted from July 28, 2025 to Aug 01, 2025.

This approval confirms the facility's compliance with FDA quality standards and regulatory requirements.

Granules Life Sciences Private Limited is engaged in the manufacturing of PFI & Finished Dosages.